New drug zilucoplan shows promise for muscle weakness in myasthenia gravis patients
NCT ID NCT06815133
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how well a new drug called Zilucoplan works for people with myasthenia gravis, a disease that causes muscle weakness. Researchers will track 55 French patients over three months to see if the drug improves muscle strength and daily life, and check for side effects. The goal is to find a better treatment option for this challenging condition.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYASTHENIA GRAVIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU NICE
RECRUITINGNice, Alpes Maritimes, 06000, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can tracking daily life unlock myasthenia gravis mysteries?
- Can engineered immune cells tame a debilitating autoimmune disease?
- Can pregnancy and neurological disease coexist safely? a new registry seeks answers
- Can DNA reveal the roots of a rare muscle disease?
- Can a simple blood test unlock the secrets of brain autoimmune diseases?
- Could a new drug help keep myasthenia gravis symptoms at bay?